Soligenix Aims To Push The Boundaries In Treating Rare Diseases

Christopher J. Schaber, Ph.D, president and CEO of Soligenix Inc. SNGX, was recently a guest on Benzinga's All-Access. Soligenix, a late-stage biopharmaceutical company, is focused on developing and commercializing treatments for rare diseases. The company’s key focus is on HyBryte™, a novel photodynamic therapy for cutaneous T-cell lymphoma, and the expansion of synthetic hypericin into psoriasis and other inflammatory diseases. Schaber shared exciting updates from the company's phase 3 study of HyBryte. Preliminary results are expected in mid 2026.